Not available
Quote | Neuren Pharms Ltd Ord (OTCMKTS:NURPF)
Last: | $13.45 |
---|---|
Change Percent: | 0.0% |
Open: | $13.45 |
Close: | $13.45 |
High: | $13.45 |
Low: | $13.45 |
Volume: | 100 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Neuren Pharms Ltd Ord (OTCMKTS:NURPF)
(NewsDirect) Neuren Pharmaceuticals Ltd (ASX:NEU) CEO Jon Pilcher speaks with Proactive following the news that its North America partner Acadia Pharmaceuticals has received US Food and Drug Administration approval of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult an...
Message Board Posts | Neuren Pharms Ltd Ord (OTCMKTS:NURPF)
Subject | By | Source | When |
---|---|---|---|
Stock_Tracker: Latest Neuren Pharmaceutica (NURPF) Headlines Fragile X Syndrome - Pipeline Review, H | Stock_Tracker | investorshangout | 03/11/2014 12:26:31 AM |
chartguy89: NURPF 0.10 Stock Charts $NURPF 1 Month Chart | chartguy89 | investorshangout | 03/09/2014 3:48:16 AM |
chartguy89: NURPF Stock Charts Last: +0.005 Friday, February 28, 2014 at 9:51:15 AM $NURPF 1 | chartguy89 | investorshangout | 02/28/2014 2:51:26 PM |
News, Short Squeeze, Breakout and More Instantly...
Neuren Pharms Ltd Ord Company Name:
NURPF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Neuren Pharmaceuticals Ltd (ASX:NEU) CEO Jon Pilcher speaks with Proactive following the news that its North America partner Acadia Pharmaceuticals has received US Food and Drug Administration approval of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult an...